STOCK TITAN
  1. Home
  2. News
  3. ABBV

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

News
SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
Rhea-AI Summary
AbbVie announced that the British Journal of Dermatology has published results from a Phase 4 study comparing SKYRIZI® (risankizumab) to Otezla® (apremilast) for the treatment of adult patients with moderate plaque psoriasis. The study showed that significantly more patients achieved the co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16 with risankizumab compared to apremilast. Higher treatment satisfaction scores were also reported for risankizumab. The study demonstrated the efficacy and safety of SKYRIZI and provides evidence supporting it as a treatment option for adults with moderate psoriasis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
clinical trial
-
News
AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
Rhea-AI Summary
AbbVie has initiated a Phase 3 trial to evaluate the efficacy and safety of upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). HS is a chronic, inflammatory disease with limited treatment options. The trial will focus on patients who have failed anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy for HS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
clinical trial
-
News
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Rhea-AI Summary
AbbVie has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the conditional marketing authorization of epcoritamab (TEPKINLY®) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. DLBCL accounts for approximately 30 percent of all global cases of non-Hodgkin's lymphoma (NHL). The final decision from the European Commission is expected later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
News
AbbVie to Host Second-Quarter 2023 Earnings Conference Call
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences earnings
-
News
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
clinical trial
-
News
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
clinical trial
News
AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
News
AbbVie Declares Quarterly Dividend
Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.48 per share. The dividend is payable on August 15, 2023, to stockholders of record on July 14, 2023. AbbVie has increased its dividend by 270 percent since its inception in 2013 and is a member of the S&P Dividend Aristocrats Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
dividends
-
News
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
Rhea-AI Summary
Genmab's epcoritamab added to NCCN Clinical Practice Guidelines for B-cell Lymphomas as third-line therapy and preferred regimen for histologic transformation of indolent lymphomas to DLBCL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
none
News
Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
clinical trial
Stock ABBV logo
Abbvie Inc

NYSE:ABBV

ABBV Rankings

#28 Ranked by Market Cap
#2312 Ranked by Stock Gains
#934 Ranked by Dividends

ABBV Stock Data

287.80B
1.76B
0.11%
71.92%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.